January 2026 – Genprex

Genprex Provides Clinical Update on Diabetes Gene Therapy Program

January 7, 2026Press Releases

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and Studies AUSTIN, Texas — (Jan. 7, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced a clinical program update on its diabetes gene therapy program […]

Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies

January 6, 2026Press Releases

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy in Type 2 Diabetic Non-Human Primates GPX-002 Rejuvenated Exhausted Beta Cells and Normalized Glucose Levels in Type 2 Diabetic Mice AUSTIN, Texas — (Jan. 6, 2026) — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for […]

Designed and Secured by Barsec